- Recorded product revenue of $349.5 million for the third
quarter, representing an 82% increase from $192.5 million in the
prior-year period
- BRUKINSA product revenue totaled $155.5 million, increasing
136% globally versus the third quarter of 2021, led by growth in
the U.S.
- Tislelizumab revenue in China reached $128.2 million, a 67%
increase over the prior year period
- BRUKINSA achieved superior Progression-Free Survival vs.
IMBRUVICA in final analysis of Phase 3 ALPINE trial
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
biotechnology company developing and commercializing innovative and
affordable oncology medicines to improve treatment outcomes and
access for far more patients worldwide, today reported financial
results for the third quarter of 2022, recent business highlights,
and anticipated upcoming milestones.
“BeiGene generated strong product revenue in the third quarter,
led by growth of our internally developed cornerstone assets,
BRUKINSA® and tislelizumab, and BRUKINSA has now been approved in
more than 55 markets around the world,” said John V. Oyler,
Co-Founder, Chairman and Chief Executive Officer of BeiGene. “We
are delighted with the recently reported positive topline results
from the final progression-free survival analysis of BRUKINSA
compared to IMBRUVICA®, which supports our confidence in BRUKINSA
as a potential new treatment that can provide hope for patients and
families with CLL. We look forward to sharing the full data with
the medical and patient communities, to important milestones in the
coming months and to a strong finish for 2022.”
“Our third quarter results underscore our commercial
capabilities and the commitment of our more than 9,000 colleagues
across 29 countries and regions to operating with excellence,” said
Julia Wang, Chief Financial Officer, BeiGene. “Following the close
of the third quarter, our total product revenue this year has now
exceeded $1 billion, an exciting milestone for the company. BeiGene
is well positioned to leverage its financial strength and multiple
upcoming catalysts for long-term growth.”
Third Quarter 2022 Financial
Results
Cash, Cash Equivalents, Restricted Cash, and Short-Term
Investments were $5.1 billion as of September 30, 2022, and
$6.6 billion as of December 31, 2021.
- In the three months ended September 30, 2022, cash used in
operating activities was $561.9 million, primarily due to our net
loss of $557.6 million and an increase in our net operating assets
and liabilities of $88.0 million, offset by non-cash charges of
$83.7 million. Net loss for the three months ended September 30,
2022, includes $125.6 million of other losses due primarily to the
strengthening of the U.S. dollar and the related revaluation of
foreign currencies held by U.S. functional currency subsidiaries.
Capital expenditures were $108.7 million and cash provided by
financing activities was $120.2 million. In addition, the impact of
foreign currency deposits being translated into the U.S. dollar
negatively impacted ending cash by $62.7 million in the three
months ended September 30, 2022.
Revenue for the three months ended September 30, 2022,
was $387.6 million, compared to $206.4 million in the same period
of 2021.
- Product revenue totaled $349.5 million for the three months
ended September 30, 2022, compared to $192.5 million in the same
period of 2021, including:
- Global sales of BRUKINSA of $155.5 million for the third
quarter of 2022, compared to $65.8 million in the prior year
period;
- Sales of tislelizumab in China of $128.2 million for the third
quarter of 2022, compared to $77.0 million in the prior year
period;
- Sales of Amgen in-licensed products in China of $27.5 million
for the third quarter of 2022, compared to $20.8 million in the
prior-year period. Prior-year period sales do not include sales of
KYPROLIS®, which was launched in China in January 2022; and
- Sales of BMS in-licensed products in China of $22.4 million for
the third quarter of 2022, compared to $26.0 million in the prior
year period.
- Collaboration revenue for the three months ended September 30,
2022, was $38.1 million, resulting from partial recognition of the
upfront payments from Novartis of $650.0 million related to the
tislelizumab agreement and $300.0 million related to the
ociperlimab option agreement, which were entered into in the first
quarter and fourth quarter of 2021, respectively. Collaboration
revenue for the three months ended September 30, 2021, was $14.0
million, resulting from the partial recognition of revenue related
to the tislelizumab agreement.
Expenses for the three months ended September 30, 2022,
were $826.0 million, compared to $668.8 million in the same period
of 2021.
- Cost of Sales for the three months ended September 30,
2022, were $76.5 million, compared to $47.4 million in the same
period of 2021. Cost of sales increased primarily due to increased
product sales of BRUKINSA and tislelizumab, as well as BLINCYTO,
which commenced in August 2021, and KYPROLIS and POBEVCY®, which
commenced in January 2022.
- R&D Expenses for the three months ended September
30, 2022, were $426.4 million, compared to $351.9 million in the
same period of 2021. The increase in R&D expenses was primarily
attributable to increases in headcount and costs related to
investment in our discovery and development activities, including
our continued efforts to internalize research and clinical
development activities, as well as increased upfront fees for
in-process R&D. Upfront fees related to in-process R&D for
in-licensed assets totaled $20.0 million and nil in the third
quarters of 2022 and 2021, respectively. Employee share-based
compensation expense also contributed to the overall increase in
R&D expenses and was $36.4 million for the three months ended
September 30, 2022, compared to $31.7 million for the same period
of 2021.
- SG&A Expenses for the three months ended September
30, 2022, were $322.9 million, compared to $269.2 million in the
same period of 2021. The increase in SG&A expenses was
primarily attributable to increased headcount, largely related to
the expansion of our commercial teams, higher professional service
fees and higher external commercial expenses, including selling and
marketing, market access studies and promotional activities. The
overall increase in SG&A expenses was also attributable to
higher SG&A-related employee share-based compensation expense,
which was $41.8 million and $35.4 million for the third quarters of
2022 and 2021, respectively.
- Operating Loss for the three months ended September 30,
2022, decreased by $24.0 million, or 5.2%, to $438.4 million,
compared to $462.3 million in the same period of 2021. The decrease
in operating loss for the quarter was driven by increased gross
profit on product sales, which exceeded the growth in operating
expenses.
- Net Loss for the quarter ended September 30, 2022, was
$557.6 million, or $0.41 per share, and $5.39 per American
Depositary Share (ADS), compared to $438.1 million, or $0.36 per
share, and $4.72 per ADS in the same period of 2021. Net loss for
the quarter was negatively impacted by other non-operating expenses
of $125.6 million, primarily related to foreign exchange losses
resulting from the strengthening of the U.S. dollar and the
revaluation impact of foreign currencies held in U.S. functional
currency subsidiaries.
Recent Business
Highlights
Commercial Operations
- Product sales increased 82% in the third quarter of 2022
compared to the prior-year period, primarily due to increased sales
of our internally developed products, BRUKINSA and tislelizumab, as
well as increased sales of in-licensed products from Amgen and
Bio-Thera;
- Global sales of BRUKINSA totaled $155.5 million in the third
quarter, representing a 136% increase compared to the prior-year
period. U.S. sales of BRUKINSA totaled $108.1 million in the third
quarter, representing growth of 221% compared to the prior year
period, as the U.S. prescribing base continued to grow and as
clinician use increased within approved indications — mantle cell
lymphoma (MCL), Waldenstr�m’s macroglobulinemia (WM) and marginal
zone lymphoma (MZL). BRUKINSA sales in China totaled $39.5 million
in the third quarter, representing growth of 23% compared to the
prior-year period, driven by a continued increase in all approved
indications, for a leading position in the China BTK market;
- Sales of tislelizumab in China totaled $128.2 million in the
third quarter, representing a 67% increase compared to the prior
year period. Approval of additional indications this year resulted
in higher market penetration and market share in the third quarter
for tislelizumab, and we saw higher new patient demand from broader
reimbursement in the National Reimbursement Drug List; and
- The National Institute for Health and Care Excellence (NICE)
issued a final appraisal document recommending BRUKINSA for the
treatment of WM in adults who have had at least one treatment, only
if bendamustine plus rituximab is also suitable, marking the first
and only treatment for WM to be recommended by NICE for routine use
in England and Wales.
Development Programs
BRUKINSA® (zanubrutinib), a small molecule inhibitor of
Bruton’s tyrosine kinase (BTK) designed to maximize BTK occupancy
and minimize off-target effects, approved in 58 markets including
the U.S., China, European Union (EU), Great Britain, Canada,
Australia, South Korea and Switzerland in selected indications and
under development for additional approvals globally. The global
BRUKINSA development program includes more than 4,700 subjects
enrolled to-date in more than 25 countries and regions.
- Announced that BRUKINSA achieved superior Progression-Free
Survival (PFS) versus ibrutinib in a final analysis of the Phase 3
ALPINE trial, as assessed by an independent review committee (IRC)
and investigator;
- Received European Commission approval for BRUKINSA for the
treatment of MZL, making BRUKINSA the first and only BTK inhibitor
for MZL approved in the European Union;
- Received positive opinion from the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency
(EMA) recommending approval of BRUKINSA for the treatment of adults
with chronic lymphocytic leukemia (CLL); and
- Expanded BRUKINSA’s registration program globally in new
geographies and indications, including launches in 10 additional
markets year-to-date.
Tislelizumab, a humanized IgG4 anti-PD-1 monoclonal
antibody specifically designed to minimize binding to FcγR on
macrophages; approved in China in nine indications and under
development for additional approvals globally. The global
tislelizumab clinical development program includes more than 11,500
subjects enrolled to-date in 30 countries and regions. Highlights
include:
- Announced acceptance by the Center for Drug Evaluation (CDE) of
the NMPA for a supplemental biologics application (sBLA) for
tislelizumab in combination with chemotherapy as a first-line (1L)
treatment in patients with unresectable locally advanced, recurrent
or metastatic esophageal squamous cell carcinoma (ESCC);
- A new drug application of tislelizumab in 1L and second-line
(2L) non-small cell lung cancer (NSCLC) and 2L esophageal cancer is
under review by MedSafe in New Zealand;
- A new drug application of tislelizumab in 2L esophageal cancer
is under review by the South Korea Ministry of Food and Safety
(MFDS);
- Announced that the global Phase 3 RATIONALE 301 trial with
tislelizumab met its primary endpoint of non-inferior Overall
Survival (OS) versus sorafenib as a 1L treatment in adult patients
with unresectable hepatocellular carcinoma (HCC). These data were
accepted as a late-breaking abstract and presented in an oral
session at the European Society for Medical Oncology Congress 2022
(ESMO 2022);
- Shared a poster demonstrating a consistent response for
tislelizumab in RATIONALE 303 across pre-specified subgroups in a
Phase 3 trial of 2L NSCLC at ESMO 2022; and
- Presented clinical data at 2022 World Conference on Lung
Cancer, including final analysis of the global, Phase 3 RATIONALE
303 trial (NCT03358875) with tislelizumab monotherapy compared to
chemotherapy in previously treated advanced NSCLC.
Ociperlimab (BGB-A1217), an investigational anti-TIGIT
monoclonal antibody with competent Fc function. The global
ociperlimab development program includes more than 25 countries and
regions, and more than 1,500 subjects have been enrolled.
- Presented data from Phase 1 trial (NCT04047862) in combination
with tislelizumab in PD-L1 expressing NSCLC at the 2022 World
Conference on Lung Cancer (WCLC); and
- Presented additional data from Phase 1 cohorts in combination
with tislelizumab and chemotherapy in NSCLC at ESMO 2022.
BGB-11417, an investigational highly selective and highly
potent inhibitor of BCL-2, being developed as monotherapy or in
combination with zanubrutinib. The global BGB-11417 development
program includes more than 10 countries and regions, and more than
300 subjects have been enrolled.
- Initiated patient dosing in Phase 2 study (NCT05471843) to
evaluate BCL-2 inhibitor BGB-11417 in patients with relapsed or
refractory mantle cell lymphoma.
- Initiated patient dosing in BGB-11417-202 study, a single-arm
phase 2 study to evaluate BGB-11417 in patients with RR CLL/SLL,
conducted in China.
Early-Stage Programs
- Initiated patient dosing in the Phase 1 trial (NCT05494762) of
BGB-B167, an investigational first-in-class CEA x 4-1BB bispecific
antibody, as a monotherapy and in combination with tislelizumab in
patients with selected CEA-expressing advanced or metastatic solid
tumors, including colorectal cancer (CRC);
- Initiated enrollment of surzebiclimab (BGB-A425) an anti-TIM3
antibody in combination with tislelizumab in tumor specific cohorts
of NSCLC and head and neck squamous cell carcinoma (HNSCC)
(NCT03744468); and
- Continued to advance our early-stage clinical pipeline of
internally developed product candidates at dose escalation stage,
including:
- BGB-A445: an investigational non-ligand competing OX40
monoclonal antibody, as monotherapy in tumor specific cohorts of
NSCLC and HNSCC or in combination with tislelizumab in advanced
solid tumors;
- BGB-15025: an investigational, first-in-class hematopoietic
progenitor kinase 1 (HPK1) inhibitor as monotherapy or in
combination with tislelizumab in solid tumors;
- BGB-16673: an investigational Chimeric Degradation Activating
Compound (CDAC), targeting BTK protein degradation as monotherapy
in B cell malignancies;
- BGB-24714: an investigational Second Mitochondrial-derived
Activator of Caspase, or SMAC, mimetic as monotherapy or in
combination with paclitaxel in advanced solid tumors;
- BGB-10188: an investigational PI3Kδ inhibitor as monotherapy or
in combination with BRUKINSA in hematology malignancies, or in
combination with tislelizumab in solid tumors; and
- BGB-23339: a potent, allosteric investigational tyrosine kinase
2 (TYK2) inhibitor.
Collaboration Programs
- In collaboration with Nanjing Leads Biolabs, initiated patient
dosing in the BeiGene-sponsored 900-102 clinical trial of LAG3
inhibitor LBL-007 in combination with tislelizumab in advanced
solid tumors (NCT03744468).
Manufacturing Operations
- Construction continues on the U.S. flagship commercial-stage
manufacturing and clinical R&D campus at the Princeton West
Innovation Campus in Hopewell, N.J. The property has more than one
million square feet of developable real estate for potential future
expansion;
- Continued construction on our new small molecule manufacturing
campus in Suzhou, China. Phase 1 of construction is expected to
bring more than 52,000 square meters and expand production capacity
to 600 million tablets/capsules and be completed in 2023. Once
completed, qualified, and approved, the total production capacity
is expected to increase our small molecule manufacturing capability
in China by up to a total of ten times capacity; and
- Continued construction on our state-of-the-art biologics
facility in Guangzhou, China, which currently is approved for
16,000 liters of biologics capacity, with an additional phase of
construction to bring total capacity to 54,000 liters expected to
be completed and GMP-ready by the end of 2022 and an additional
10,000 liters in the second quarter of 2023.
Corporate Developments
- Entered into a strategic alliance with Ontada®, a McKesson
business with leading provider technology and actionable real-world
research, education, and evidence in oncology, to improve U.S.
community oncology care through the development of real-world
evidence (RWE) data, tools, and insights to help increase access to
affordable, cutting-edge therapies.
Expected Milestones
BRUKINSA
- Continue to support ongoing FDA review of the sNDA for
CLL/small lymphocytic lymphoma, which has a PDUFA target action
date of January 2023;
- Continue to support the European Medicines Agency (EMA) and
European Commission for the approval of new indication applications
for CLL;
- Continue to support Health Canada review of sNDA for CLL;
- Continue to support NMPA review of sNDA for 1L CLL/SLL in
China;
- Continue to support the review of MHRA and Swissmedic for new
indication application for MZL and CLL;
- Present final analysis data for the global Phase 3 ALPINE trial
(NCT03734016) including progression-free survival at an upcoming
medical congress; and
- Present key data from BRUKINSA clinical development programs at
64th American Hematology Association Meeting (December 10-14, New
Orleans) including an oral presentation for BRUKINSA in MZL
(MAGNOLIA trial), and a poster with updated results for BRUKINSA in
acalabrutinib-intolerant patients with B-cell malignancies.
Tislelizumab
- Continue to support NMPA review of BLA application for
tislelizumab in combination with chemotherapy as a 1L treatment for
patients with advanced or metastatic gastric or gastroesophageal
junction adenocarcinoma whose tumors express PD-L1, and for
tislelizumab in combination with chemotherapy as a 1L treatment in
patients with unresectable locally advanced, recurrent or
metastatic ESCC;
- Continue interaction with NMPA for sBLA for tislelizumab as a
treatment for 1L hepatocellular carcinoma;
- Continue to support review by regulatory authorities of
BeiGene's applications for tislelizumab including: Australia’s TGA
review and New Zealand's Medsafe review of BLA for tislelizumab in
1L/2L NSCLC and 2L ESCC, and South Korea's MFDS review of BLA for
tislelizumab in 2L ESCC;
- In collaboration with Novartis, continue to support review of
marketing applications including:
- Ongoing FDA review of the BLA submission in 2L ESCC including
facilitating scheduling the required inspections as soon as
possible;
- EMA review of marketing authorization applications for
tislelizumab in 1L/2L NSCLC and 2L ESCC;
- UK MHRA review of tislelizumab for treatment of 1L/2L NSCLC and
2L ESCC in Great Britain via Reliance route;
- Swiss Medic review of marketing authorization applications for
tislelizumab in 2L ESCC; and
- Support U.S. FDA regulatory submission by Novartis in 2023 for
1L gastric cancer, 1L unresectable ESCC, and 1L HCC.
BGB-11417 (BCL-2)
- Present Phase 1 clinical data for non-Hodgkin's lymphoma, CLL,
acute myeloid leukemia (AML) and multiple myeloma (MM)
(NCT04883957, NCT04277637, NCT04771130, and NCT04973605) at ASH
2022.
Collaboration Programs
- In collaboration with Zymeworks, announce topline results for a
Phase 2b clinical trial of zanidatamab in advanced or metastatic
HER2-amplified biliary tract cancers (NCT04466891) in 2022.
COVID-19 Impact and Response
We expect that the worldwide health crisis of COVID-19 will
continue to have a negative impact on our operations, including
commercial sales, regulatory interactions, inspections, filings,
manufacturing, and clinical trial recruitment, participation, and
data readouts. There remains uncertainty regarding the future
impact of the pandemic both globally and specifically in China due
to outbreaks and restrictions and potential impact on clinical,
manufacturing and commercial operations. We are striving to
minimize delays and disruptions, have put protocols and procedures
in place, and continue to execute on our commercial, regulatory,
manufacturing, and clinical development goals globally.
Financial
Summary Select Condensed Consolidated Balance Sheet
Data (U.S. GAAP) (Amounts in thousands of U.S. Dollars)
As of
September 30,
December 31,
2022
2021 1
(unaudited)
Assets:
Cash, cash equivalents, restricted cash
and short-term investments
$
5,072,510
$
6,624,849
Accounts receivable, net
189,170
483,113
Inventories
290,911
242,626
Property and equipment, net
681,914
587,605
Total assets
6,726,013
8,535,525
Liabilities and equity:
Accounts payable
252,071
262,400
Accrued expenses and other payables
410,255
558,055
Deferred revenue
294,883
407,703
R&D cost share liability
319,973
390,362
Debt
649,333
629,678
Total liabilities
2,070,842
2,402,962
Total equity
$
4,655,171
$
6,132,563
Condensed Consolidated Statements of Operations (U.S.
GAAP)
(Amounts in thousands of U.S. dollars, except for shares,
American Depositary Shares (ADSs), per share and per ADS data)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022
2021 1
2022 1
2021 1
(Unaudited)
(Unaudited)
Revenue:
Product revenue, net
$ 349,506
$ 192,461
$ 915,590
$ 437,202
Collaboration revenue
38,122
13,979
120,236
525,102
Total revenues
387,628
206,440
1,035,826
962,304
Expenses:
Cost of sales - products
76,543
47,413
212,953
116,361
Research and development
426,363
351,937
1,194,485
1,028,754
Selling, general and administrative
322,892
269,227
948,868
683,622
Amortization of intangible assets
187
188
563
563
Total expenses
825,985
668,765
2,356,869
1,829,300
Loss from operations
(438,357)
(462,325)
(1,321,043)
(866,996)
Interest income (expense), net
12,759
(2,230)
34,261
(11,275)
Other (loss) income, net
(125,640)
31,477
(243,290)
26,487
Loss before income taxes
(551,238)
(433,078)
(1,530,072)
(851,784)
Income tax expense
6,318
5,036
28,408
15,354
Net loss
(557,556)
(438,114)
(1,558,480)
(867,138)
Net loss per share attributable to
BeiGene, Ltd.:
Basic and diluted
$ (0.41)
$ (0.36)
$ (1.16)
$ (0.72)
Weighted-average shares outstanding:
Basic and diluted
1,345,303,747
1,205,971,284
1,337,976,853
1,196,391,201
Net loss per ADS attributable to BeiGene,
Ltd.:
Basic and diluted
$ (5.39)
$ (4.72)
$ (15.14)
$ (9.42)
Weighted-average ADSs outstanding:
Basic and diluted
103,484,904
92,767,022
102,921,296
92,030,092
1 We revised certain prior period financial statements for an
error related to the valuation of net deferred tax assets, the
impact of which was immaterial to our previously filed financial
statements in the first and second quarters of 2022 and the
quarterly and annual periods of fiscal 2021 (see "Notes to the
Condensed Consolidated Financial Statements, Note 1. Description of
Business, Basis of Presentation and Consolidation and Significant
Accounting Policies" and "Note 2. Revision of Prior Period
Financial Statements" included in our Quarterly Report on Form 10-Q
for the period ended September 30, 2022 filed with the SEC).
About BeiGene
BeiGene is a global biotechnology company that is developing and
commercializing innovative and affordable oncology medicines to
improve treatment outcomes and access for far more patients
worldwide. With a broad portfolio, we are expediting development of
our diverse pipeline of novel therapeutics through our internal
capabilities and collaborations. We are committed to radically
improving access to medicines for far more patients who need them.
Our growing global team of more than 9,000 colleagues spans five
continents, with administrative offices in Beijing, China;
Cambridge, U.S.; and Basel, Switzerland. To learn more about
BeiGene, please visit www.beigene.com and follow us on Twitter at
@BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
clinical data for BeiGene’s drug candidates and approvals of its
medicines; the conduct of late-stage clinical trials and expected
data readouts; additional planned product approvals and launches;
the advancement of and anticipated clinical development, regulatory
approvals and other milestones and commercialization of BeiGene’s
medicines and drug candidates; the potential for BRUKINSA to
provide clinical benefit to patients with CLL compared with the
comparator drug; the success of BeiGene’s commercialization efforts
and revenue growth; the expected capacities and completion dates
for the Company’s manufacturing facilities under construction; the
impact of the COVID-19 pandemic on the Company’s clinical
development, regulatory, commercial, manufacturing, and other
operations; expectations for BeiGene’s strategic alliance with
Ontada; BeiGene’s plans and the expected events and milestones
under the captions “Recent Business Highlights” and “Expected
Milestones”; and BeiGene’s plans, commitments, aspirations and
goals under the caption “About BeiGene”. Actual results may differ
materially from those indicated in the forward-looking statements
as a result of various important factors, including BeiGene's
ability to demonstrate the efficacy and safety of its drug
candidates; the clinical results for its drug candidates, which may
not support further development or marketing approval; actions of
regulatory agencies, which may affect the initiation, timing and
progress of clinical trials and marketing approval; BeiGene's
ability to achieve commercial success for its marketed medicines
and drug candidates, if approved; BeiGene's ability to obtain and
maintain protection of intellectual property for its medicines and
technology; BeiGene's reliance on third parties to conduct drug
development, manufacturing, commercialization, and other services;
BeiGene’s limited experience in obtaining regulatory approvals and
commercializing pharmaceutical products and its ability to obtain
additional funding for operations and to complete the development
of its drug candidates and achieve and maintain profitability; the
impact of the COVID-19 pandemic on BeiGene’s clinical development,
regulatory, commercial, manufacturing, and other operations, as
well as those risks more fully discussed in the section entitled
“Risk Factors” in BeiGene’s most recent quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in BeiGene's subsequent filings with the
U.S. Securities and Exchange Commission. All information in this
press release is as of the date of this press release, and BeiGene
undertakes no duty to update such information unless required by
law.
BLINCYTO® and KYPROLIS® are registered trademarks of Amgen.
POBEVCY® is a registered trademark of Bio-Thera Solutions, Ltd.
IMBRUVICA® is a registered trademark of Pharmacyclics LLC and
Janssen Biotech, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221108006299/en/
Investors Kevin Mannix +1 857-302-5189 ir@beigene.com
Media Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024